H2S-releasing drugs: Anti-inflammatory, cytoprotective and chemopreventative potential

Nitric Oxide - Biology and Chemistry

Volumn 46, Issue , 2015, Pages 25-31

  Gemici, Burcu ^a   Elsheikh, Wagdi ^b   Feitosa, Karla B ^c   Costa, Soraia K P ^c   Muscara, Marcelo N ^c   Wallace, John L ^b,d,e  

^a NEAR EAST UNIVERSITY   (Turkey)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cytoprotection; Drug development; Gastrointestinal; Hydrogen sulfide; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CYTOPROTECTIVE AGENT; HYDROGEN SULFIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTECTIVE AGENT;

ABERRANT CRYPT FOCUS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; CANCER INHIBITION; CANCER PREVENTION; CELL PROTECTION; COLON CANCER; DIGESTIVE SYSTEM ULCER; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EXPERIMENTAL MODEL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; HUMAN; IN VITRO STUDY; INFLAMMATION; INTESTINE CANCER; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LONG TERM CARE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH BLOOD FLOW; TREATMENT DURATION; VASCULAR ENDOTHELIUM; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; HYDROGEN SULFIDE; PROTECTIVE AGENTS;

EID: 84924709971     PISSN: 10898603     EISSN: 10898611     Source Type: Journal    
DOI: 10.1016/j.niox.2014.11.010     Document Type: Review

References (56)

1. M.V. Chan, and J.L. Wallace Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments Am. J. Physiol. Gastrointest. Liver Physiol 305 2013 G467 G473
2. 2S-releasing drugs as pharmaceuticals J. Med. Chem 53 2010 6275 6286
3. R.C.O. Zanardo, V. Brancaleone, E. Distrutti, S. Fiorucci, G. Cirino, and J.L. Wallace Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation FASEB J. 20 2006 2118 2120
4. H.B. Ma, S. Huang, X.R. Yin, Y. Zhang, and Z.L. Di Apoptotic pathway induced by diallyl trisulfide in pancreatic cancer cells World J. Gastroenterol 20 2014 193 203
5. Z.W. Lee, X.Y. Teo, E.Y. Tay, C.H. Tan, T. Hagen, and P.K. Moore Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance Br. J. Pharmacol 171 2014 4322 4336
6. S. Fiorucci, E. Antonelli, E. Distrutti, G. Rizzo, A. Mencarelli, and S. Orlandi Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs Gastroenterology 129 2005 1210 1224
7. K.L. Flannigan, T.A. Agbor, R.W. Blackler, J.J. Kim, W.I. Khan, and E.F. Verdu Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis Proc. Natl Acad. Sci. U.S.A. 111 2014 13559 13564
8. A.F. Kamath, A.K. Chauhan, J. Kisucka, V.S. Dole, J. Loscalzo, and D.E. Handy Elevated levels of homocysteine compromise blood-brain barrier integrity in mice Blood 107 2006 591 593 s
9. Q. Guan, X. Wang, L. Gao, J. Chen, Y. Liu, and C. Yu Hydrogen sulfide suppresses high glucose-induced expression of intercellular adhesion molecule-1 in endothelial cells J. Cardiovasc. Pharmacol 62 2013 278 284
10. S. Fiorucci, S. Orlandi, A. Mencarelli, G. Caliendo, V. Santagada, and E. Distrutti Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis Br. J. Pharmacol 150 2007 996 1002
11. L. Li, G. Rossoni, A. Sparatore, L.C. Lee, P. Del Soldato, and P.K. Moore Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative Free Radic. Biol. Med 42 2007 706 719
12. Z. Palinkas, P.G. Furtmuller, A. Nagy, C. Jakopitsch, K.F. Pirker, and M. Magierowski Interactions of hydrogen sulfide with myeloperoxidase Br. J. Pharmacol 2014 10.1111/bph.12769
13. C.N. Serhan, S.D. Brain, C.D. Buckley, D.W. Gilroy, C. Haslett, and L.A.J. O'Neill Resolution of inflammation: state of the art, definitions and terms FASEB J. 21 2007 325 332
14. N. Dufton, J. Natividad, E.F. Verdu, and J.L. Wallace Hydrogen sulfide and resolution of acute inflammation: a comparative study utilizing a novel fluorescent probe Scientific Rep 2 2012 499
15. O. Zayachkivska, O. Havryluk, N. Hrycevych, N. Bula, O. Grushka, and J.L. Wallace Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis PLoS ONE 9 2014 e110688
16. N. Sen, B.D. Paul, M.M. Gadalla, A.K. Mustafa, T. Sen, and R. Xu Hydrogen sulfide-linked sulfhydration of NFkB mediates its antiapoptotic actions Mol. Cell 45 2012 13 24
17. N.J. Davidson, M.W. Leach, M.M. Fort, L. Thompson-Snipes, R. Kühn, and W. Müller T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice J. Exp. Med 184 1996 241 251
18. J.L. Wallace Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract Antiox. Redox Signal 12 2010 1125 1133
19. J.L. Wallace, R.W. Blackler, M.V. Chan, G.J. da Silva, K.L. Flannigan, and I. Gamaniek Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics Antioxid. Redox Signal 2014 24635322
20. J.L. Wallace, M. Dicay, W. McKnight, and G.R. Martin Hydrogen sulfide enhances ulcer healing in rats FASEB J. 21 2007 4070 4076
21. J.L. Wallace, L. Vong, W. McKnight, M. Dicay, and G.R. Martin Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats Gastroenterology 137 2009 569 578
22. R.W. Blackler, J.P. Motta, A. Manko, M. Workentine, P. Bercik, and M.G. Surette Hydrogen sulfide protects against NSAID-enteropathy through modulation of bile and the microbiota Br. J. Pharmacol 2014 10.1111/bph.12961
23. A. Papapetropoulos, Z. Pyriochou, G. Altaany, A. Yang, Z. Marazioti, and M.G. Zhou Hydrogen sulfide is an endogenous stimulator of angiogenesis Proc. Natl Acad. Sci. U.S.A. 106 2009 21972 21977
24. R.W. Blackler, B. Gemici, A. Manko, and J.L. Wallace NSAID-gastroenteropathy: new aspects of pathogenesis and prevention Curr. Opin. Pharmacol 19 2014 11 16
25. J.L. Wallace, G. Caliendo, V. Santagada, G. Cirino, and S. Fiorucci Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat Gastroenterology 132 2007 261 271
26. J.L. Wallace, G. Caliendo, V. Santagada, and G. Cirino Markedly reduced toxicity of a hydrogen sulfide-releasing derivative of naproxen (ATB-346) Br. J. Pharmacol 159 2010 1236 1246
27. J.L. Wallace Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol. Rev 88 2008 1547 1565
28. - secretion Curr. Med. Chem 19 2012 43 54
29. S.A. Mard, H. Askari, N. Neisi, and A. Veisi Antisecretory effect of hydrogen sulfide on gastric acid secretion and the involvement of nitric oxide BioMed Res. Int 2014 2014 480921 10.1155/2014/480921
30. J.L. Wallace, C.M. Keenan, and D.N. Granger Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process Am. J. Physiol 259 1990 G462 G467
31. J.L. Wallace NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies Br. J. Pharmacol 165 2012 67 74
32. J.L. Wallace Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy World J. Gastroenterol 19 2013 1861 1876
33. J.L. Wallace, S. Syer, E. Denou, G. de Palma, L. Vong, and W. McKnight Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis Gastroenterology 141 2011 1314 1322
34. R. Blackler, S. Syer, M. Bolla, E. Ongini, and J.L. Wallace Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence PLoS ONE 7 2012 e35196
35. J.P. Motta, K.L. Flannigan, T.A. Agbor, J.K. Beatty, R.W. Blackler, and M.L. Workentine Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production Inflamm. Bowel Dis 2014 in press
36. P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, and C. Patrono Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 332 2006 1302 1308
37. D.M. McCafferty, D.N. Granger, and J.L. Wallace Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats Gastroenterology 109 1995 1173 1180
38. C. Sostres, and A. Lanas Gastrointestinal effects of aspirin Nat. Rev. Gastroenterol. Hepatol 8 2011 385 394
39. A. Lanas, L.A. García-Rodríguez, M. Polo-Tomás, M. Ponce, I. Alonso-Abreu, and M.A. Perez-Aisa Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice Am. J. Gastroenterol 104 2009 1633 1641
40. J.L. Wallace Polypharmacy of osteoarthritis: the perfect intestinal storm Dig. Dis. Sci 58 2013 3088 3093
41. J.L. Wallace, G. Cirino, V. Santagada, G. Caliendo, Hydrogen sulfide derivatives of nonsteroidal anti-inflammatory drugs, United States Patent Application No. WO/2008/009127 (2008).
42. A. LoGuidice, B.D. Wallace, L. Bendel, M.R. Redinbo, and U.A. Boelsterli Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice J. Pharmacol. Exp. Ther 341 2012 447 454
43. C. Patrono, and B. Rocca Aspirin: promise and resistance in the new millennium Arteriosclerosis Thromb. Vasc. Biol 28 2008 S25 S32
44. R.S. Sandler, S. Halabi, J.A. Baron, S. Budinger, E. Paskett, and R. Keresztes A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N. Engl. J. Med 348 2003 883 890
45. R.F. Logan, J. Little, P.G. Hawtin, and J.D. Hardcastle Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme BMJ 307 1993 285 289
46. J.R. Goodman, and D. Grossman Aspirin and other NSAIDs as chemoprevention agents in melanoma Cancer Prev. Res 7 2014 557 564
47. E. Yiannakopoulou Targeting epigenetic mechanisms and microRNAs by aspirin and other nonsteroidal anti-inflammatory agents - implications for cancer treatment and chemoprevention Cell. Oncol 37 2014 167 178
48. J.L. Wallace, A. Bak, G.W. McKnight, S. Asfaha, K.A. Sharkey, and W.K. MacNaughton Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity Gastroenterology 115 1998 101 109
49. K. Kashfi Anti-cancer activity of new designer hydrogen sulfide-donating hybrids Antioxid. Redox Signal 20 2014 831 846
50. W. Elsheikh, R.W. Blackler, K.L. Flannigan, and J.L. Wallace Enhanced chemopreventative effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer Nitric Oxide 41 2014 131 137
51. J.M. Ward, R.S. Yamamoto, and C.A. Brown Pathology of intestinal neoplasms and other lesions in rats exposed to azoxymethane J. Nat. Cancer Inst 51 1973 1029 1039
52. E.A. McLellan, and R.P. Bird Specificity study to evaluate induction of aberrant crypts in murine colons Cancer Res 48 1988 6183 6186
53. A.R. Moser, C. Luongo, K.A. Gould, M.K. McNeley, A.R. Shoemaker, and W.F. Dove ApcMin: a mouse model for intestinal and mammary tumorigenesis Eur. J. Cancer 31A 1995 1061 1064
54. S.J. Baek, R. Okazaki, S.H. Lee, J. Martinez, J.S. Kim, and K. Yamaguchi Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia Gastroenterology 131 2006 1553 1560
55. G. Yang, K. Zhao, Y. Ju, S. Mani, Q. Cao, and S. Puukila Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2 Antiox. Redox Signal 18 2013 1906 1919
56. H.B. Ma, S. Huang, X.R. Yin, Y. Zhang, and Z.L. Di Apoptotic pathway induced by diallyl trisulfide in pancreatic cells World J. Gastroenterol 20 2014 193 203